KRAS and non-small cell lung carcinoma: Collective evidence has demonstrated that the KRAS gene mutation status serves as a biomarker to predict the prognosis of NSCLC patients after chemotherapy [31]; however, KRAS and EGFR mutations are mutually exclusive, and NSCLC patients with KRAS mutations have a low response rate to EGFR-TKIs [32].